Mr. Brent Zettl reports

ZYUS LIFE SCIENCES ANNOUNCES STRATEGIC REALIGNMENT TO PRIORITIZE DRUG DEVELOPMENT

Zyus Life Sciences Corp. is strategically realigning its corporate structure and leadership to strengthen its focus on the company's core clinical development priorities.

As part of this realignment, the company will streamline operations by discontinuing its international business development activities. This decision is intended to reduce overhead costs and redirect resources toward the company's drug development programs. The company will also initiate a formal wind-down of its international legal entities.

In connection with this strategic realignment, Keith Carpenter, chief strategy and investment officer, will step down from his role, effective June 11, 2026. A key member of the company's executive team since 2018, Mr. Carpenter was an instrumental figure in many facets of the business over the past eight years. The company thanks Mr. Carpenter for his contributions and dedication to Zyus, and wishes him well in his future endeavours.

"This realignment reflects our commitment to focusing resources on the areas that we believe will create the greatest value for patients and shareholders," said Brent Zettl, president and chief executive officer of Zyus. "By streamlining our operations, we are sharpening our focus on advancing our clinical-stage non-opioid drug development programs. We believe these actions will strengthen our operational efficiency and position the company to deliver on its key clinical development objectives."

About Zyus Life Sciences Corp.

Zyus is a life science company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions in pursuit of the transformational impact on patients' lives.

We seek Safe Harbor.